Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry


06 Mar 2023


Cocktail & Poster Display session


Corinne Vannier


Annals of Oncology (2023) 8 (1suppl_2): 100896-100896. 10.1016/esmoop/esmoop100896


C. Vannier1, U.M. Martens2, A. Bleckmann3, M. Zaiss4, N. Burkhart5, T. Decker6, S. Kaldune7, C. Langer8, M. Looß9, L. Hillebrand9, O. Vahtrik10, M. Frank10, B. Niemeier11, K.M. Potthoff1, B. Kasenda12

Author affiliations

  • 1 Medical Department, iOMEDICO, 79106 - Freiburg/DE
  • 2 Oncology Department, Klinik Für Innere Medizin Iii, SLK-Kliniken Heilbronn GmbH, 74078 - Heilbronn/DE
  • 3 Hematology, Oncology And Cccm Department, UKM - University Hospital Muenster, 48149 - Muenster/DE
  • 4 Oncology Dept., Praxis fuer interdisziplinaere Onkologie und Haematologie GbR, 79110 - Freiburg im Breisgau/DE
  • 5 Oncology, Asklepios Klinik Altona, 20144 - Hamburg/DE
  • 6 Oncology Department, Onkologie Hämatologie Ravensburg, Onkologie Hamatologie Ravensburg, 88212 - Ravensburg/DE
  • 7 Medizinsche Klinik Iii, RoMed Klinikum Rosenheim, 83022 - Rosenheim/DE
  • 8 Onclogy, Hematology And Palliative Care, Klinikum Kempten-Oberallgaeu gGmbH, 87439 - Kempten/DE
  • 9 Medical Department, iOMEDICO AG, 79106 - Freiburg im Breisgau/DE
  • 10 Statistical Department, iOMEDICO AG, 79106 - Freiburg im Breisgau/DE
  • 11 Clinical Operations, iOMEDICO AG, 79106 - Freiburg im Breisgau/DE
  • 12 Medical Oncology Department, Universitatsspital Basel, 4031 - Basel/CH


This content is available to ESMO members and event participants.

Abstract 67P


Neurotrophic Tyrosine Receptor Kinase gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the tropomyosin receptor kinases TRKA, TRKB and TRKC, respectively) are oncogenic drivers. The overall prevalence of NTRK fusion-positive tumors is ∼0.30%, though frequencies vary by tumor type, with >90% reported for some rare tumor types such as secretory carcinoma of the breast and salivary glands. In Europe, the TRK inhibitors (TRKi) entrectinib and larotrectinib, both showing high clinical activity and favorable safety profiles, have received tumor-agnostic approval based on pooled data of non-comparative phase I/II clinical trials with limited patient numbers.


REALTRK is a retro- and prospective, observational, intersectoral, multicenter cohort study in Germany and Switzerland (NCT04557813). Enrollment of 120 patients (pts) with advanced solid tumors harboring an NTRK fusion diagnosed with a validated assay according to ESMO recommendations is planned. Pts with detailed information on NTRK testing qualify for complete documentation, including demographic and clinical characteristics, details on NTRK testing, treatment, outcome, and safety of TRKi. Furthermore, physician-reported factors on NTRK testing and treatment decision making as well as patient-reported outcomes on quality of life (EORTC QLQ-C30) are assessed.


At data cut-off (Sept 30th, 2022), 18 pts have been enrolled at 13 sites in Germany and Switzerland. Of those, 12 pts were eligible for complete documentation. Median age at diagnosis of NTRK fusion was 60.7 years and median time from NTRK fusion diagnosis to start of TRKi therapy, received by 11 pts, was 0.9 months. Tumor entities and data on NTRK fusions are presented in the table.


REALTRK provides valuable data on NTRK testing and treatment reality of pts with NTRK fusion-positive solid tumors and generates clinically relevant real-world evidence. Table: 67P

Tumor entity NTRK gene Fusion partner gene
CNS tumor (including glioma) NTRK1 PRCC
Colorectal cancer NTRK1 LMNA
Lung cancer (NSCLC/SCLC) NTRK1 KIF5B
Soft tissue sarcoma NTRK3 ETV6
Thyroid cancer NTRK3 ETV6

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study



Roche GmbH.


A. Bleckmann: Financial Interests, Personal, Advisory Role: Alexion, Gilead, Novartis, Bristol-Myers Squibb, Bayer, Servier, Roche, AstraZeneca, Takeda, Merck, BeiGene, MSD, Lilly, ArtTempi, Jannsen-Cilag, Amgen, Boehringer Ingelheim. M. Zaiss: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Esai, Gilead, Hexal, Jannsen, Lilly, Novartis, Pierre-Fabre, Pfizer, Roche, Vifor. T. Decker: Financial Interests, Personal, Advisory Board: Novartis, iOMEDICO. B. Kasenda: Financial Interests, Personal, Advisory Board: Astellas, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.